Ordering
Available Variants5 mg
CHA.30166-5mg
Price
€111.20
Available – Dispatch in 14 days
25 mg
CHA.30166-25mg
Price
€440.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.30166-5mg | €111.20 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.30166-25mg | €440.00 |
≥98% (HPLC), FFA2/FFAR2/GPCR43/GPR43 antagonist , powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C25H25ClN2O4S |
|---|---|
| CAS Number | 1391076-61-1 |
| Molecular Weight | 485.00 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
| MDL number | MFCD28502087 |
| Assay | ≥98% (HPLC) |
| Form | powder |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
GLPG0974, also known by its CAS number 1391076-61-1, is a small molecule inhibitor that has been investigated for its potential therapeutic applications. This compound has been studied in various preclinical models, where it has demonstrated promising activity. GLPG0974 is believed to exert its effects through the modulation of specific biological pathways, leading to potential benefits in certain disease areas. Further research is needed to fully elucidate the mechanisms of action and potential uses of GLPG0974, as well as to assess its safety and efficacy in human subjects. As with any experimental compound, additional studies are required to determine the suitability of GLPG0974 for clinical development and potential regulatory approval. Ongoing research efforts aim to provide a more comprehensive understanding of this compound and its potential role in addressing unmet medical needs.
